Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502258 | 0.81 | — | — | |
| SCHEMBL73986 | 0.78 | ESR1 (0.32) | — | |
| SCHEMBL21345875 | 0.77 | — | — | |
| SCHEMBL7176145 | 0.75 | SLC6A2 (0.34) | — | |
| SCHEMBL502576 | 0.73 | BRS3 (0.31) | — | |
| SCHEMBL22482128 | 0.73 | — | — | |
| SCHEMBL12311899 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22384006 | 0.73 | — | — | |
| SCHEMBL28400748 | 0.71 | — | — | |
| SCHEMBL11192016 | 0.70 | MEN1 (0.35) | MEN1USP2ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422349-B2 | N-terminal modified exendin-4 | HANMI SCIENCE CO., LTD (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9072794-B2 | Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity | HANMI SCIENCE CO., LTD (KR) | 2015-07-07 | — | — | US | disclosed |
| US-8895281-B2 | Method for preparing a site-specific physiologically active polypeptide conjugate | HANMI SCIENCE CO., LTD (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8476230-B2 | Insulinotropic complex using an immunoglobulin fragment | HANMI SCIENCE CO., LTD (KR) | 2013-07-02 | — | — | US | disclosed |
| US-20130122023-A1 | NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-16 | — | — | US | disclosed |
| US-20100204451-A1 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2010-08-12 | — | — | US | disclosed |
| US-20100105877-A1 | AN INSULINOTROPIC COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090238838-A1 | INSULINOTROPIC PEPTIDE CONJUGATE USING AN IMMUNOGLOBULIN FC | HANMI PHARM. IND. CO. LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204451-A1 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED | IAPP, GLP1R, GPR119 | MEN1 133/4885USP2 3199/4885ALDH1A1 4760/4885 |
| US-20130122023-A1 | NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY | GLP1R, GIPR, GCG | MEN1 1168/4885USP2 1215/4885ALDH1A1 4270/4885 |
| US-20090238838-A1 | INSULINOTROPIC PEPTIDE CONJUGATE USING AN IMMUNOGLOBULIN FC | IAPP, GPR119, INSR | MEN1 483/4885USP2 3412/4885ALDH1A1 4507/4885 |
| US-20100105877-A1 | AN INSULINOTROPIC COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT | IAPP, INSR, GPR119 | MEN1 590/4885USP2 3991/4885ALDH1A1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.